Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, June 30, 2021
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Tue, June 29, 2021
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
David Nierengarten Maintained (BEAM) at Buy with Increased Target to $149 on, Jun 29th, 2021
David Nierengarten of Wedbush, Maintained "Beam Therapeutics Inc." (BEAM) at Buy with Increased Target from $114 to $149 on, Jun 29th, 2021.
David has made no other calls on BEAM in the last 4 months.
There are 2 other peers that have a rating on BEAM. Out of the 2 peers that are also analyzing BEAM, all agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Luca Issi of "RBC Capital" Initiated at Hold and Held Target at $85 on, Tuesday, May 4th, 2021
- Gena Wang of "Barclays" Downgraded from Buy to Hold and Increased Target to $90 on, Monday, March 1st, 2021
